Methodological aspects of health‐related quality of life measurement and analysis in patients with multiple myeloma
- 17 January 2019
- journal article
- review article
- Published by Wiley in British Journal of Haematology
- Vol. 185 (1) , 11-24
Abstract
Summary: Multiple myeloma (MM) is an incurable but treatment‐sensitive cancer. For most patients, this means treatment with multiple lines of anti‐myeloma therapy and a life with disease‐ and treatment‐related symptoms and complications. Health‐related quality of life (HRQoL) issues play an important role in treatment decision‐making. Methodological challenges in longitudinal HRQoL measurements and analyses have been identified, including non‐responses (NR) to scheduled questionnaires. Publications were identified for inclusion in a systematic review of longitudinal HRQoL studies in MM, focussing on methodological aspects of HRQoL measurement and analysis. Diversity in timing of HRQoL data collection and applied statistical methods were noted. We observed a high rate of NR, but the impact of NR was investigated in only 8/23 studies. Thus, evidence‐based knowledge of HRQoL in patients with MM is compromised. To improve quality of HRQoL results and their implementation in daily practice, future studies should follow established guidelines.Keywords
Funding Information
- Kræftens Bekæmpelse
- Syddansk Universitet
This publication has 93 references indexed in Scilit:
- Review of health-related quality of life data in multiple myeloma patients treated with novel agentsLeukemia, 2013
- Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trialBlood, 2013
- Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple MyelomaJournal of Clinical Oncology, 2013
- Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trialHaematologica, 2012
- Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized studyEuropean Journal of Haematology, 2012
- Investigating the missing data mechanism in quality of life outcomes: a comparison of approachesHealth and Quality of Life Outcomes, 2009
- Multiple myelomaBlood, 2008
- Improved survival in multiple myeloma and the impact of novel therapiesBlood, 2008
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1993